Systemic options for atopic dermatitis continue to present limitations

When weighing use of systemic therapies for severe atopic dermatitis (AD) physicians must consider potential side effects, such as liver and kidney toxicity and myelosuppression, according to Wynnis L. Tom, M.D.

Related Videos
Related Content

European Commission Approves Secukinumab for Hidradenitis Suppurativa

June 1st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Amgen to Present New MOSAIC Phase 4 Data at EULAR 2023

June 1st 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

For Patients With Birthmarks, Psychosocial Interventions Improved Wellbeing

May 31st 2023

Janssen Announces Positive Results From Guselkumab Psoriatic Arthritis Trial

May 31st 2023

European Commission Approves Secukinumab for Hidradenitis Suppurativa

June 1st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Amgen to Present New MOSAIC Phase 4 Data at EULAR 2023

June 1st 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

For Patients With Birthmarks, Psychosocial Interventions Improved Wellbeing

May 31st 2023

Janssen Announces Positive Results From Guselkumab Psoriatic Arthritis Trial

May 31st 2023

European Commission Approves Secukinumab for Hidradenitis Suppurativa

June 1st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Amgen to Present New MOSAIC Phase 4 Data at EULAR 2023

June 1st 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

For Patients With Birthmarks, Psychosocial Interventions Improved Wellbeing

May 31st 2023

Janssen Announces Positive Results From Guselkumab Psoriatic Arthritis Trial

May 31st 2023
© 2023 MJH Life Sciences

All rights reserved.